# Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)

> **NCT06610734** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 202 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Chemotherapy
- **RADIATION:** low dose radiotherapy

## Key facts

- **NCT ID:** NCT06610734
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-23
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610734, "Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT06610734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*